Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.67 |
| ▸ | KMO | O15229 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4561027 | 0.99 | SLC6A4 (0.65) | SLC6A4SLC6A3KMOHRH3SLC6A2 | |
| SCHEMBL4932960 | 0.80 | SLC6A4 (1.00) | SLC6A4SLC6A3KMOHRH3SLC6A2 | |
| SCHEMBL14190994 | 0.79 | HRH3 (0.71) | SLC6A4SLC6A3HRH3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4384101 | 0.78 | HRH3 (0.71) | SLC6A4SLC6A3HRH3MEN1KMT2A | |
| SCHEMBL4377267 | 0.75 | SLC6A4 (0.55) | SLC6A4SLC6A3HRH3SLC6A2MEN1 | |
| SCHEMBL4377271 | 0.75 | SLC6A4 (0.55) | SLC6A4SLC6A3HRH3SLC6A2MEN1 | |
| Hydrochloric Acid SCHEMBL4375762 | 0.74 | SLC6A4 (0.54) | SLC6A4SLC6A3HRH3SLC6A2MEN1 | |
| Hydrochloric Acid SCHEMBL4378691 | 0.74 | SLC6A4 (0.54) | SLC6A4SLC6A3HRH3SLC6A2MEN1 | |
| SCHEMBL4383222 | 0.72 | HRH3 (0.64) | SLC6A4SLC6A3HRH3KMT2A | |
| Hydrochloric Acid SCHEMBL4378288 | 0.71 | HRH3 (0.65) | HRH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | SLC6A4 858/4885SLC6A3 652/4885KMO 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.